|Bid||1.3500 x 1300|
|Ask||1.6000 x 800|
|Day's range||1.3100 - 1.5600|
|52-week range||1.0750 - 15.9100|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Potential Angion Biomedica Corp. ( NASDAQ:ANGN ) shareholders may wish to note that the President, Jay Venkatesan...
Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.